Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Nov;64(5):907–910. doi: 10.1038/bjc.1991.424

Epidermal growth factor receptors (EGFR) in human ovarian cancer.

O J Owens 1, C Stewart 1, I Brown 1, R E Leake 1
PMCID: PMC1977444  PMID: 1931614

Abstract

Epidermal growth factor receptor can be used as a biological marker in tumours. We examined 199 samples from 150 patients with ovarian cancer first by using a single point screen, then by full Scatchard analysis, over a concentration range between 0.086-16.6 nM. Taking as positive those samples which showed a 20% difference between total binding and non specific binding, the EGFR was present in 39.7% of samples ranging from 36.4% in those tumours which were classified as being mucinous to 47.7% in the undifferentiated group. Thirty-six samples had a low affinity component (Kd greater than 1 nM), 27 had a high affinity component (Kd less than 1 nM) and 16 had both high and low affinity components to the EGFR. There was no statistical difference between degree of differentiation of the tumour and the presence of the EGFR nor between stage of the disease and EGFR presence.

Full text

PDF
907

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauknecht T., Kohler M., Janz I., Pfleiderer A. The occurrence of epidermal growth factor receptors and the characterization of EGF-like factors in human ovarian, endometrial, cervical and breast cancer. EGF receptors and factors in gynecological carcinomas. J Cancer Res Clin Oncol. 1989;115(2):193–199. doi: 10.1007/BF00397923. [DOI] [PubMed] [Google Scholar]
  2. Bauknecht T., Runge M., Schwall M., Pfleiderer A. Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas. Gynecol Oncol. 1988 Feb;29(2):147–157. doi: 10.1016/0090-8258(88)90209-0. [DOI] [PubMed] [Google Scholar]
  3. Crawford D., Cowan S., Hyder S., McMenamin M., Smith D., Leake R. New storage procedure for human tumor biopsies prior to estrogen receptor measurement. Cancer Res. 1984 Jun;44(6):2348–2351. [PubMed] [Google Scholar]
  4. Fitzpatrick S. L., Brightwell J., Wittliff J. L., Barrows G. H., Schultz G. S. Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels. Cancer Res. 1984 Aug;44(8):3448–3453. [PubMed] [Google Scholar]
  5. Hofmann G. E., Rao C. V., Barrows G. H., Schultz G. S., Sanfilippo J. S. Binding sites for epidermal growth factor in human uterine tissues and leiomyomas. J Clin Endocrinol Metab. 1984 May;58(5):880–884. doi: 10.1210/jcem-58-5-880. [DOI] [PubMed] [Google Scholar]
  6. Korc M., Padilla J., Grosso D. Epidermal growth factor inhibits the proliferation of a human endometrial carcinoma cell line. J Clin Endocrinol Metab. 1986 May;62(5):874–880. doi: 10.1210/jcem-62-5-874. [DOI] [PubMed] [Google Scholar]
  7. Neal D. E., Sharples L., Smith K., Fennelly J., Hall R. R., Harris A. L. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer. 1990 Apr 1;65(7):1619–1625. doi: 10.1002/1097-0142(19900401)65:7<1619::aid-cncr2820650728>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  8. Nicholson S., Halcrow P., Sainsbury J. R., Angus B., Chambers P., Farndon J. R., Harris A. L. Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br J Cancer. 1988 Dec;58(6):810–814. doi: 10.1038/bjc.1988.315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Roos W., Fabbro D., Küng W., Costa S. D., Eppenberger U. Correlation between hormone dependency and the regulation of epidermal growth factor receptor by tumor promoters in human mammary carcinoma cells. Proc Natl Acad Sci U S A. 1986 Feb;83(4):991–995. doi: 10.1073/pnas.83.4.991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Sainsbury J. R., Farndon J. R., Needham G. K., Malcolm A. J., Harris A. L. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987 Jun 20;1(8547):1398–1402. doi: 10.1016/s0140-6736(87)90593-9. [DOI] [PubMed] [Google Scholar]
  11. Sainsbury J. R., Farndon J. R., Sherbet G. V., Harris A. L. Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet. 1985 Feb 16;1(8425):364–366. doi: 10.1016/s0140-6736(85)91385-6. [DOI] [PubMed] [Google Scholar]
  12. Schlessinger J. The epidermal growth factor receptor as a multifunctional allosteric protein. Biochemistry. 1988 May 3;27(9):3119–3123. doi: 10.1021/bi00409a002. [DOI] [PubMed] [Google Scholar]
  13. Shepherd J. H. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol. 1989 Aug;96(8):889–892. doi: 10.1111/j.1471-0528.1989.tb03341.x. [DOI] [PubMed] [Google Scholar]
  14. Wyss R., Fabbro D., Regazzi R., Borner C., Takahashi A., Eppenberger U. Phorbol ester and epidermal growth factor receptors in human breast cancer. Anticancer Res. 1987 Jul-Aug;7(4B):721–727. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES